Psyence Group is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the disorders such as anxiety, depression and PTSD. Additionally, the company are focusing on using the healing potential of psychedelics to help people overcome issues related to stress, grief and bereavement. Psyence are focusing on the context of palliative care.
Psyence Group
The company is invested in scientific research and creating regulatory-compliant psilocybin-containing products for research institutions and clinics. Psyence operates one of the first federally licensed commercial psilocybin cultivation and production facilities in the world which is located in the Kingdom of Lesotho. Psyence is also in the functional mushroom market, with their GOODMIND product now available to consumers.
Psyence Group Inc. announced that it expects to receive U$1.58 million in funding after announcing a non-brokered private placement offering.
News
- “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts (Globe Newswire, September 2021)
Activities
B2B
B2C
Manufacturing
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates